Global Divalproex Sodium Market Size (2024 - 2029)

Divalproex Sodium Market Analysis

The divalproex sodium market is projected to register a CAGR of 6.2% during the forecast period, 2022-2027.

The COVID-19 pandemic has been continuing to transform the growth of various markets, and the immediate impact of the outbreak is varied. While a few industries registered a drop in demand, numerous other markets may continue to remain unscathed and show promising growth opportunities. For instance, according to an article published in March 2020 titled "Epilepsy and COVID-19: Updated Evidence and Narrative Review," a survey of 212 pediatric neurologists from 49 countries found that in-person outpatient visits have decreased, and telemedicine use was increased during the pandemic. Thus, COVID-19 has a significant impact on the growth of the market in the initial phase. However, the demand for divalproex sodium is expected to rise at a considerable pace in the coming years.

Moreover, the major factors responsible for the growth of the divalproex sodium market include the growing incidence rates of bipolar disorders, rising patient pool with epilepsy and migraine headaches, increasing government initiatives, and rising research and development to introduce new products.

The increasing prevalence of bipolar disorders worldwide is propelling market growth. As per an article titled 'What is the worldwide prevalence of bipolar disorder?' published in October 2021, bipolar disorder has a lifetime prevalence of about 1% and a one-year prevalence of about 0.5% worldwide. Bipolar I disorder has greater rates than bipolar II disorder.According to World Health Organization (WHO) key facts updated in June 2022, 1 in every 8 people in the world live with a mental disorder. Due to the COVID-19 pandemic, the number of people who suffer from anxiety and depressive illnesses greatly increased in 2020. Initial projections indicate a 26% and 28% increase in depressive disorders and anxiety, respectively, in just one year. As per the same source, in 2020, 40 million people experienced bipolar disorder.

Moreover, globally, the expanding patient pool affected with epilepsy and migraine headaches is also expected to significantly boost the demand in the divalproex sodium market. For instance, as per the World Health Organization's update of February 2022, around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. In high-income countries, there are an estimated 49 per 100,000 patients that are diagnosed with epilepsy each year. In low- and middle-income countries, this figure can be as high as 139 per 100,000. Such a high burden of epilepsy creates the need for treatment and thus drives the growth of the market.

Furthermore, the increasing awareness regarding diseases and various government initiatives to prevent migraines are expected to propel the growth of the divalproex sodium market. For instance, in November 2021, in the United States, November is celebrated as National Epilepsy Awareness Month (NEAM). Every year, the Epilepsy Foundation, in collaboration with the Epilepsy Foundation, launches the #RemoveTheFilter social media campaign to reduce fear surrounding epilepsy and bring hope to those facing challenges. Such awareness campaigns are also expected to contribute to the growth of the market.

However, black boxed warning given by the Food and Drug Administration due to the hepatotoxicity, pancreatitis, and high fetal risk associated with the use of divalproex sodium tablet and other known adverse reactions such as birth defects, neurobehavioral adverse effects, and suicidal behavior are expected to restrain the divalproex sodium market growth.

Divalproex Sodium Industry Segmentation

As per the scope of the report, divalproex sodium is an anti-epileptic drug that is prescribed to patients with bipolar disorder, migraine headaches, and certain types of seizures. This drug is known for its anticonvulsant property for the treatment of epilepsy. The divalproex sodium market is segmented by product type (tablet, capsules, and syrup), application (epilepsy, manic-depressive illness, and other applications), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.